Aarti Pharmalabs (NSE:AARTIPHARM) Forward Dividend Yield %: 0.58% (As of Jun. 28, 2026)


NSE:AARTIPHARM Aarti Pharmalabs Ltd NSE:AARTIPHARM
56 GF Score
Price ₹690.70
GF Value ₹636.14
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Aarti Pharmalabs Forward Dividend Yield %?

Aarti Pharmalabs NSE:AARTIPHARM -2.73% 56 Forward Dividend Yield % is 0.58% as of Jun. 28, 2026. GuruFocus rates NSE:AARTIPHARM with a GF Score™ of 56/100 and a GF Value™ of ₹636.14 (Fairly Valued). The stock has 3 warning signs investors should review. Among 505 Drug Manufacturers companies, Aarti Pharmalabs ranks worse than 80.2% on this metric.

As of today (2026-06-28), the Forward Annual Dividend Yield of Aarti Pharmalabs is 0.58%.

As of today (2026-06-28), the Trailing Annual Dividend Yield of Aarti Pharmalabs is 0.58%.

NSE:AARTIPHARM's Forward Dividend Yield % is ranked worse than
80.2% of 505 companies
in the Drug Manufacturers industry
Industry Median: 2.14 vs NSE:AARTIPHARM: 0.58

Aarti Pharmalabs's Dividends per Share for the three months ended in Mar. 2026 was ₹1.50.

During the past 12 months, Aarti Pharmalabs's average Dividends Per Share Growth Rate was 14.30% per year.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.


Aarti Pharmalabs  (NSE:AARTIPHARM) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.


Aarti Pharmalabs Forward Dividend Yield % Related Terms


NSE:AARTIPHARM vs ZTS: Forward Dividend Yield % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Aarti Pharmalabs's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aarti Pharmalabs Forward Dividend Yield % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aarti Pharmalabs's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Aarti Pharmalabs's Forward Dividend Yield % falls into.


NSE:AARTIPHARM
56GF Score
Aarti Pharmalabs Ltd NSE:AARTIPHARM
Forward Dividend Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aarti Pharmalabs Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

Aarti Pharmalabs Recent Full-Year* Dividend History

Amount Ex-date Record Date Pay Date Type Frequency Forex Rate
INR 1.5000002026-02-162026-02-162026-02-27Cash Dividendsemi-annuallyINR:INR 1.000000
INR 2.5000002025-09-152025-09-152025-10-01Cash Dividendsemi-annuallyINR:INR 1.000000

* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.

Aarti Pharmalabs's Forward Annual Dividend Yield (%) for Today is calculated as

Forward Annual Dividend Yield=Forward Full Year Dividend/Current Share Price
=3/690.70
=0.43 %

Current Share Price is ₹690.70.
Aarti Pharmalabs's Dividends per Share for the forward twelve months is calculated as ₹1.5 * 2 = ₹3.

Aarti Pharmalabs's Trailing Annual Dividend Yield (%) for Today is calculated as

Trailing Annual Dividend Yield=Most Recent Full Year Dividend/Current Share Price
=4/690.70
=0.58 %

Current Share Price is ₹690.70.
Aarti Pharmalabs's Dividends per Share for the trailing twelve months (TTM) ended in Today is ₹4.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Forward Dividend Yield % of 0.58% mean?
Aarti Pharmalabs (NSE:AARTIPHARM) has a Forward Dividend Yield % of 0.58% as of Jun. 28, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Aarti Pharmalabs and its competitors. According to the industry distribution chart, Aarti Pharmalabs ranks #405 out of 505 companies in the Drug Manufacturers industry, placing it in the top 80.2%.
Is Aarti Pharmalabs' Forward Dividend Yield % too high?
Aarti Pharmalabs' current Forward Dividend Yield % is 0.58%. The Drug Manufacturers industry median Forward Dividend Yield % is 2.14. Aarti Pharmalabs' value of 0.58% is 72.9% below this industry median. Based on the distribution chart, Aarti Pharmalabs ranks #405 out of 505 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Aarti Pharmalabs has a GF Score™ of 56/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Aarti Pharmalabs' Forward Dividend Yield % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Aarti Pharmalabs ranks #405 out of 505 companies for Forward Dividend Yield %. This places Aarti Pharmalabs in the lower half of its industry. The industry median Forward Dividend Yield % is 2.14. Aarti Pharmalabs' value of 0.58% is 72.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Drug Manufacturers company?
The median Forward Dividend Yield % among Drug Manufacturers companies is 2.14, based on 505 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aarti Pharmalabs's current Forward Dividend Yield % of 0.58% is 72.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Aarti Pharmalabs and its competitors. For the Drug Manufacturers industry, the median Forward Dividend Yield % is 2.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aarti Pharmalabs's current Forward Dividend Yield % is 0.58%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aarti Pharmalabs stock overvalued right now?
Based on GuruFocus' analysis, Aarti Pharmalabs (NSE:AARTIPHARM) is currently considered Fairly Valued. The stock's GF Value™ is ₹636.14, compared to a current price of ₹690.70 — trading 8.6% above its estimated fair value. The current Forward Dividend Yield % is 0.58% and 72.9% below the Drug Manufacturers industry median of 2.14. Aarti Pharmalabs' overall GF Score™ is 56/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Aarti Pharmalabs (NSE:AARTIPHARM), the current Forward Dividend Yield % is 0.58% as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aarti Pharmalabs (NSE:AARTIPHARM) Overvalued in 2026?

Based on GuruFocus' analysis, Aarti Pharmalabs stock appears to be overvalued. The current stock price of ₹690.70 is trading 8.6% above its estimated GF Value™ of ₹636.14. GuruFocus considers Aarti Pharmalabs to be Fairly Valued.

Key valuation signals for NSE:AARTIPHARM:

  • Forward Dividend Yield %: 0.58%
  • GF Value™: ₹636.14 vs. price of ₹690.70 (8.6% above fair value)
  • GF Score™: 56/100 with 3 warning signs
  • Industry Position: 72.9% below the Drug Manufacturers median (#405 of 505)

No single metric tells the full story. See the NSE:AARTIPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Aarti Pharmalabs Business Description

Other Exchanges 543748:India
Address Mulund Goregaon Link Road, 204, 2nd Floor, Udyog Kshetra, Mulund West, Mumbai, MH, IND, 400080
Aarti Pharmalabs Ltd manufactures pharmaceuticals and nutraceuticals with a footprint. The company manufactures Active Pharmaceutical Ingredients (API), pharmaceutical intermediates, acids, and xanthine derivatives, including caffeine, theophylline anhydrous, aminophylline, etophylline, and theophylline in India. It also offers Contract Development and Manufacturing Services (CDMS) for drug substance (NCE, RSM, Intermediates) projects. Geographically, the company generates maximum revenue from its customers located outside India.
56GF Score

Get the complete analysis for NSE:AARTIPHARM

Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹690.70
Price
₹636.14
GF Value